BCL7A and lung cancer: Utilizing HuProtTM, Pan et al. identified novel autoantibodies with enhanced sensitivities of 50% for the IgG panel (against p53, HRas, and ETHE1) and 73.5% for the combined IgG–IgA panel (against BCL7A, TRIM33, MTERF4, CTAG1A, DDX4, and MAGEC2), while maintaining a specificity of over 85% for early lung cancer detection [23,35].